OR WAIT null SECS
Multi-national digital therapeutics (DTx) innovator Sidekick Health has secured the services of two highly experienced U.S.-based healthcare professionals to expand the company's global footprint and lead the expansion in the U.S. healthcare market.
Sidekick operates a scalable digital care platform in partnership with some of the biggest names in pharmaceuticals and healthcare, including Pfizer and Bayer, to augment pharmacotherapy, develop integrated combination therapeutics consisting of a drug (Rx) and a DTx, as well as to create standalone prescription DTx (PDT).
The company has also partnered with leading health insurers in the U.S., focusing on the support of the 30% multi-chronic population that drives 70% of healthcare costs, aiming to help them manage their symptoms, provide regular remote patient monitoring, and prevent serious illness and hospital visits.
CEO and co-founder Tryggvi Thorgeirsson, says: "In order to continue our groundbreaking work, Sidekick must attract the best talent in the industry. Pamela and Mitchell exemplify the Sidekick ethos - between them, they have decades of expertise and industry knowledge, which we look forward to putting to use as Sidekick continues on its mission to prevent unnecessary death and suffering by developing and delivering effective, personalized digital therapeutics to everyone with a chronic disease."
On joining Sidekick as CCO and President, North America, Pamela Stahl, says: "Sidekick exemplifies the future of our industry, and I am thrilled to be joining the company at such an exciting juncture. I look forward to continuing to create value for our existing partners, strike new partnerships, and to help more patients on their treatment journey."
Sidekick's new COO Mitchell Mudra says: "Healthcare is evolving into a much more consumer-driven industry, where convenience, personalization and clinical outcomes are critical, and Sidekick is at the forefront of this change. As the next generation of healthcare companies are created, digital therapeutics will lead the way by dramatically improving access to quality care, to the immense benefit of patients."